Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.77 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.77 |
| ▸ | TNF | P01375 | 2/20 | 0.77 |
| ▸ | IL1B | P01584 | 2/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552858 | 0.91 | DDB1 (0.73) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL17873743 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23418355 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22620261 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24132522 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23355751 | 0.89 | CRBN (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15514910 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29922261 | 0.89 | DDB1 (0.69) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24620750 | 0.88 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283120 | 0.88 | CRBN (0.68) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196567-A2 | METHODS OF TREATING A SUBJECT HAVING CLINICALLY SIGNIFICANT SIGNS AND SYMPTOMS ASSOCIATED WITH BLOOD CELL DIFFERENTIATION | FOGHORN THERAPEUTICS INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2020069106-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |